CaryHealth Introduces Direct-to-Patient Access Program for Natroba in Collaboration with Cipher Pharmaceuticals
CaryHealth, a leading provider of integrated digital healthcare solutions, has announced the launch of a new direct-to-patient (DTP) platform aimed at improving access to prescription treatments for common but highly disruptive conditions such as head lice and scabies. The platform has been developed in partnership with Cipher Pharmaceuticals US LLC and is designed to streamline the process of obtaining and receiving Natroba (spinosad), a prescription medication used to treat both conditions effectively.
This new initiative reflects a growing trend within the healthcare industry toward digital-first, patient-centric models that aim to simplify care delivery and remove friction from traditional healthcare workflows. By integrating telehealth, prescribing, pharmacy fulfillment, and delivery into a single cohesive platform, CaryHealth and Cipher Pharmaceuticals are seeking to address long-standing challenges that patients and families face when trying to access timely and effective treatments.
Head lice and scabies are highly contagious conditions that often require immediate intervention, particularly in households with children. However, accessing appropriate treatment can be time-consuming and frustrating. Patients frequently encounter barriers such as the need for in-person doctor visits, delays in obtaining prescriptions, limited pharmacy availability, and ineffective over-the-counter remedies. The newly launched DTP platform is designed to overcome these obstacles by offering a seamless, end-to-end solution that prioritizes speed, convenience, and clinical appropriateness.
Through the platform, patients can access telehealth services to obtain a prescription for Natroba (spinosad) when clinically appropriate. Once prescribed, the medication can be fulfilled through a nationwide pharmacy network, with options for either local pickup or home delivery. In select regions served by CaryHealth’s pharmacy services, same-day delivery is available, further accelerating the time from diagnosis to treatment. Additionally, patients can track the status of their prescriptions in real time through the CaryConnect digital portal, providing transparency and peace of mind throughout the process.
According to Bryan Jacobs, President of U.S. Operations at Cipher Pharmaceuticals, the partnership with CaryHealth represents a significant step forward in addressing the needs of families dealing with head lice and scabies. He emphasized that these conditions require solutions that are both fast and simple, noting that many traditional over-the-counter treatments have become less effective over time. By contrast, prescription options such as Natroba (spinosad) offer a more reliable and immediate resolution to these issues.
Jacobs also highlighted the importance of accessibility, explaining that the platform enables patients to obtain treatment quickly without the typical delays associated with traditional healthcare pathways. Whether through local pharmacy pickup or direct-to-home delivery, the goal is to ensure that patients can begin treatment as soon as possible, minimizing disruption to daily life.
From CaryHealth’s perspective, the launch of the DTP platform underscores its commitment to transforming the patient experience through digital innovation. Areo Nazari, Chief Executive Officer of CaryHealth, described the initiative as a bold and patient-centered approach that reimagines how care is delivered. He noted that by bringing together prescribing, clinical engagement, and pharmacy fulfillment into a unified system, the company is eliminating many of the inefficiencies that have historically characterized virtual care workflows.
Nazari further explained that the integrated model allows patients to move seamlessly from the initial point of care—such as a telehealth consultation—through to successful treatment, without the need to navigate multiple platforms or complete redundant steps. This streamlined approach not only enhances convenience but also improves adherence to prescribed therapies, ultimately leading to better health outcomes.
A key feature of the platform is its ability to reduce fragmentation in the patient journey. Traditional virtual care models often require patients to interact with multiple systems, including separate portals for telehealth visits, prescription management, and pharmacy services. These fragmented workflows can lead to confusion, delays, and even treatment abandonment. CaryHealth’s solution addresses this issue by consolidating all aspects of care into a single, user-friendly interface, eliminating the need for multiple logins and simplifying the overall experience.
The platform also addresses administrative challenges such as payment processing, which is often a source of friction in healthcare delivery. By integrating payment into the same system, patients can complete all necessary steps in one place, reducing the likelihood of delays or errors. This holistic approach ensures that patients can focus on their health rather than navigating complex administrative processes.
From a broader industry perspective, the launch of this DTP platform highlights the increasing role of digital health technologies in improving access to care. As healthcare systems worldwide continue to evolve, there is a growing emphasis on leveraging technology to deliver more efficient, patient-centered solutions. CaryHealth’s collaboration with Cipher Pharmaceuticals demonstrates how partnerships between digital health companies and pharmaceutical manufacturers can create innovative models that benefit both patients and providers.
In summary, the introduction of CaryHealth’s direct-to-patient platform for Natroba (spinosad) represents a significant advancement in the treatment of head lice and scabies. By combining telehealth, prescribing, pharmacy fulfillment, and delivery into a seamless digital experience, the platform addresses many of the barriers that have traditionally hindered access to care. With its focus on speed, convenience, and clinical effectiveness, this initiative has the potential to improve outcomes for patients while setting a new standard for digital healthcare delivery.
About CaryHealth
CaryHealth is an AI-enabled digital pharmacy and healthcare technology company redefining how patients start and stay on therapy. Our platform unites pharmacy services, intelligent automation, and data-driven commitment to simplify access, improve continuity of care, and empower patients throughout their treatment journey. By bridging the gap between life sciences, providers, and patients, CaryHealth advances equitable access and helps therapies reach their full potential.
For more information, visit cary.health .
About Cipher Pharmaceuticals
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher’s topical product Natroba™, and its authorized generic spinosad, is the only product that carries the US Food and Drug Administration’s (FDA’s) “Complete Cure” designation for the treatment of scabies. 1 Additionally, Natroba™ (spinosad) is the only FDA approved prescription head lice treatment that demonstrated clinical superiority to Nix® (permethrin 1%) in two head-to-head, phase III clinical trials. No nit combing required. 1
Source Link:https://www.businesswire.com/
